Dr. Pemmaraju on Clinical Trial Results of LCL161 in High-Risk Myelofibrosis

Naveen Pemmaraju, MD
Published: Tuesday, Dec 12, 2017



Naveen Pemmaraju, MD, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the clinical trial results for LCL161 in patients with intermediate or high-risk myelofibrosis.

Among the 38 patients treated at the time of analysis, 10 were responding for an overall response rate of 24% to 26%, explains Pemmaraju. The median age is 72-years-old.

Five patients have experienced long-term responses, says Pemmaraju, with response rates over 1 year. The 3 most common side effects were fatigue, nausea, and dizziness—similar to what was seen with solid tumors.
 


Naveen Pemmaraju, MD, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the clinical trial results for LCL161 in patients with intermediate or high-risk myelofibrosis.

Among the 38 patients treated at the time of analysis, 10 were responding for an overall response rate of 24% to 26%, explains Pemmaraju. The median age is 72-years-old.

Five patients have experienced long-term responses, says Pemmaraju, with response rates over 1 year. The 3 most common side effects were fatigue, nausea, and dizziness—similar to what was seen with solid tumors.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Atlanta: Advances in the Treatment of Chronic Lymphocytic LeukemiaFeb 28, 20190.5
Community Practice Connections™: 2nd Annual International Congress on Immunotherapies in Cancer™: Focus on Practice-Changing ApplicationFeb 28, 20192.0
Publication Bottom Border
Border Publication
x